Apogee Therapeutics (NASDAQ:APGE) Trading Down 6.5% – What’s Next?

Apogee Therapeutics Inc. (NASDAQ:APGE)’s share price was down 6.5% during trading on Tuesday . The stock traded as low as $74.21 and last traded at $74.0620. Approximately 344,728 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 1,014,072 shares. The stock had previously closed at $79.24.

Key Stories Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: 52‑week Phase 2 Part A data showed durable maintenance and deepening responses with every‑3‑month and every‑6‑month dosing (EASI‑75 maintenance ~75% and 85%; strong vIGA results), supporting the drug’s infrequent‑dosing commercial argument. GlobeNewswire: Positive Phase 2 Part A 52‑Week Data
• Positive Sentiment: Multiple brokerages raised price targets and reiterated buy ratings (examples: Citigroup, Canaccord, Guggenheim, BTIG), signaling stronger sell‑side conviction and helping push the stock higher earlier in the session. Benzinga: Analyst Coverage
• Positive Sentiment: Buy‑side commentary and feature pieces highlight zumilokibart’s long half‑life and convenience (Q3M/Q6M) and list near‑term catalysts: Part B 16‑week induction readout in Q2 2026 and potential Phase 3 start in H2 2026. Seeking Alpha: Strong Buy / Upcoming Catalysts
• Neutral Sentiment: Management hosted/announced calls and posted detailed slides/transcripts on the 52‑week data, increasing transparency and enabling analysts to update models. Yahoo Finance: Conference Call Announcement
• Neutral Sentiment: Independent valuation commentary (Seeking Alpha) models APGE with mixed outcomes—one DCF cited ~ $73/share—highlighting that upside may depend on commercialization path, Phase 3 plans or M&A. Seeking Alpha: Valuation / DCF
• Negative Sentiment: Apogee filed a proposed $300M underwritten public offering of common stock (plus a 30‑day option for an additional $45M), which typically creates near‑term selling pressure/dilution risk and likely contributed to later weakness in the shares. GlobeNewswire: Proposed $300M Offering

Analyst Ratings Changes

Several analysts have commented on the company. Stephens initiated coverage on Apogee Therapeutics in a report on Tuesday, December 16th. They issued an “overweight” rating and a $95.00 price target for the company. Royal Bank Of Canada cut their price objective on shares of Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating on the stock in a report on Monday, March 2nd. Wedbush boosted their target price on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Apogee Therapeutics in a report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 target price for the company. Finally, Canaccord Genuity Group increased their price target on shares of Apogee Therapeutics from $89.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Apogee Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $110.43.

Apogee Therapeutics Stock Down 7.7%

The company has a 50 day simple moving average of $71.28 and a 200 day simple moving average of $63.70. The company has a market capitalization of $5.08 billion, a price-to-earnings ratio of -17.33 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.02. On average, research analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total transaction of $1,495,600.00. Following the completion of the sale, the chief executive officer directly owned 1,152,987 shares in the company, valued at $86,220,367.86. The trade was a 1.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the completion of the sale, the director directly owned 298,647 shares of the company’s stock, valued at $22,786,766.10. The trade was a 85.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,839,700 shares of company stock valued at $140,118,083 over the last ninety days. Corporate insiders own 42.77% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC boosted its position in shares of Apogee Therapeutics by 2.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock worth $540,000 after buying an additional 152 shares during the period. Stifel Financial Corp raised its holdings in shares of Apogee Therapeutics by 3.5% during the 4th quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock valued at $394,000 after buying an additional 175 shares during the period. ANTIPODES PARTNERS Ltd lifted its position in Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after acquiring an additional 246 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new position in Apogee Therapeutics in the 4th quarter worth approximately $25,000. Finally, Comerica Bank boosted its holdings in Apogee Therapeutics by 1.0% in the 4th quarter. Comerica Bank now owns 35,872 shares of the company’s stock worth $2,708,000 after acquiring an additional 338 shares during the period. 79.04% of the stock is owned by hedge funds and other institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.